Related Experiment Video
Updated: Nov 15, 2025
06:52
Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
9.5K
Alzheimer's Disease: Pathogenesis and Therapeutic Interventions
John O Ogbodo1, Chinazom P Agbo2, Ugochi O Njoku3
1Department of Science Laboratory Technology, University of Nigeria, Nsukka, Nigeria.
Current Aging Science
|March 3, 2021
Summary
Alzheimer's Disease (AD) management focuses on early detection and intervention due to limited therapeutic success. Research explores various treatments, including diet, gene therapy, and nanotechnology for improved Alzheimer's Disease prognosis.
Area of Science:
- Neuroscience
- Biomedical Engineering
- Pharmacology
Background:
- Alzheimer's Disease (AD) is the leading cause of dementia, associated with genetic, environmental, and lifestyle factors.
- Current therapeutic strategies for AD lack complete success, underscoring the need for early detection and management.
Purpose of the Study:
- To review and discuss various interventions for Alzheimer's Disease pathogenesis.
- To explore novel therapeutic and diagnostic approaches for AD.
Main Methods:
- Literature review of therapeutic agents, gene therapy, dietary interventions (Mediterranean, Okinawan, MIND diets), and medicinal plants for AD.
- Exploration of nanotechnology, including nano-formulations and Superparamagnetic Iron Oxide Nanoparticles (SPIONs), for AD drug delivery and theranostics.
Main Results:
- Various interventions show potential in managing AD, but none offer a complete cure.
- Nanotechnology presents promising theranostic applications for early AD detection and targeted drug delivery.
Conclusions:
- Early detection and management are crucial for improving Alzheimer's Disease prognosis.
- Innovative approaches like nanotechnology offer new avenues for AD treatment and diagnosis.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
565
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
565
01:26Alzheimer's Disease: Overview
1.1K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.1K
01:15Parkinson's Disease: Overview
1.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.2K
01:30Dementia
285
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
285
03:03Amyloid Fibrils
11.1K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.1K
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
1.4K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
1.4K